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The analysis of Fgf10 mouse mutants has demonstrated a critical role for this ligand in neurosensory
development of the vertebrate inner ear, and we have been looking to deﬁne the direct upstream
regulators of Fgf10 in this sensory organ, as part of constructing the programme of early inner ear
development. Through the analysis of reporter constructs in transgenic mouse embryos and neonatal
mice, in this report we deﬁne a minimal 1400 bp enhancer from the 50 ﬂanking region of Fgf10. This
enhancer drives reporter transgene expression in a manner that recapitulates endogenous expression of
Fgf10, from its initial onset in the invaginating otic placode and onwards throughout gestation,
controlling Fgf10 expression in all developing sensory patches and in the developing VIIIth ganglion.
This regulatory region includes three putative Gata3 binding sites that we demonstrate directly
interacts with Gata3 protein through the DNA binding domain with differing afﬁnities. Site directed
mutagenesis of all three sites and functional testing in transgenic embryos using reporter transgenes
reveals an absolute requirement for Gata3 in controlling Fgf10 expression. Transgenic analysis of
individual Gata3 binding site mutations illustrates that only one of these binding sites is necessary for
reporter expression. Together these data demonstrate that Gata3 directly activates Fgf10 in the early
inner ear, and does so through a single binding site.
& 2012 Elsevier Inc. All rights reserved.Introduction
Fibroblast growth factors (FGFs) play multiple roles during
development of the mammalian inner ear. During induction of the
inner ear, competent surface ectoderm adjacent to hindbrain
rhombomeres 5 and 6 thickens to form the otic placode that
subsequently invaginates to form the otocyst (Kiernan et al.,
2002; Ohyama et al., 2007; Torres and Giraldez, 1998). Two
ligands, FGF3 and FGF10, have been shown to be redundantly
required for induction of the mouse otocyst (Alvarez et al., 2003;
Wright and Mansour, 2003), but an additional requirement for
FGF8 as well (Dominguez-Frutos et al., 2009; Ladher et al., 2005;
Zelarayan et al., 2007) indicates that the action of multiple FGFs,
derived from different periotic tissues, the hindbrain, mesoderm
and endoderm, are all required in concert for the early formation
of the inner ear (reviewed in (Schimmang, 2007)). The complexityll rights reserved.
conomou),
@ucl.ac.uk (V. Georgiadis),
n.yu.edu (D. Frenz),
Signalling & Development,
it, Rayne Institute, Universityof multiple FGFs that are expressed near the forming otic placode
has necessitated double and compound mutant analyses, together
with misexpression studies, to fully discern the distinct
role(s) individual FGFs play in inner ear induction. However, less
attention has been focused on any later redundant roles that may
also exist in the developing inner ear, since a number of FGFs are
also expressed within the developing otic epithelium. Never-
theless, additional and unique roles for both mouse Fgf3 and
Fgf10 in the otocyst itself have also been reported. Ligands from
both genes are expressed in the antero-ventral otocyst, in a
prosensory/neurogenic region where both sensory cells and
neuroblasts are born (reviewed in (Fekete, 1996; Fekete and
Wu, 2002)). This expression is consistent with the ﬁnding of a
reduced vestibulo-acoustic (VIII) ganglion in Fgf3 mutants (Hatch
et al., 2007; Mansour et al., 1993). In Fgf10 mouse mutants,
defects in both vestibular sensory neurons and hair cells have
been reported (Pauley et al., 2003); the posterior crista is absent,
with the horizontal and anterior cristae reduced and disoriented,
and whilst vestibular innervation is initiated normally, nerve
ﬁbres fail to target the missing crista, and innervation is reduced
to the remaining cristae (Pauley et al., 2003). Thus expression of
FGFs 3 and 10 in the otocyst is required for proper development of
the otic epithelium in a non-redundant manner. Additional FGFs
have also been shown to be critical for the normal development
within the otic epithelium. Both Fgf8 (Jacques et al., 2007) and
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speciﬁcation of distinct cell types in the developing organ of Corti.
Thus multiple FGFs exerting discrete roles within the same
epithelium suggests a complex upstream regulatory network that
ultimately needs to discriminate the transcriptional control of
ligand expression in different cells to execute cell-speciﬁc
functions.
In other vertebrate species, FGF expression domains within
and surrounding the developing inner ear suggest that the FGF
roles described above are likely to be conserved across species, as
has been shown to be the case for the conserved role of FGFs in
vertebrate inner ear induction, but the particular FGF members
involved in different phenotypes may be different between
species. Considering only those roles separate to induction of
the inner ear, FGF3 in the zebraﬁsh appears to be responsible
more globally for anterior patterning of the otocyst (Hammond
and Whitﬁeld, 2011; Hans et al., 2007, 2004; Hans and
Westerﬁeld, 2007; Liu et al., 2003). Zebraﬁsh FGFs 3 and 8 are
able to impose competence on epithelia to respond to forced
expression of Atoh1 to adopt a sensory fate (Sweet et al., 2011).
In the chick as in the mouse, FGFs are also involved in the normal
formation of semicircular canals. Ectopic FGF3 and FGF10 expres-
sion leads to canal dysmorphogenesis in the chick (Chang et al.,
2004), whereas Fgf10 loss in the mouse leads to loss of the
posterior canal (Pauley et al., 2003). Earlier experiments have
shown that FGF2 is also able to inﬂuence neuronal development
of the inner ear. Chick otocyst explant cultures were used to
uncover a role for FGF2 in migration and differentiation of cells in
the vestibuloacoustic ganglion (Hossain et al., 1996) and FGF2 is
able to promote the survival of cochlear neurons in vitro
(Carnicero et al., 2001). In vivo in the developing chicken inner
ear, ectopic FGF2 and FGF8 increase the size of the vestibulo-
acoustic ganglion through further recruitment of cells to
the neuroblast lineage (Adamska et al., 2001). More recently,
using chick vestibulo-acoustic ganglion explant cultures, FGFs 8,
10 and 19 were all able to promote directional neurite extension
(Fantetti and Fekete, 2012). Together these experiments indicate
that the expression domains of different FGFs in the otic epithe-
lium are associated with different developmental roles in the
inner ear.
Whilst knowledge of the detailed roles of FGFs in the inner ear
has advanced dramatically over recent years, our understanding
of the upstream molecular mechanisms linking FGFs to the early
developmental programme of the inner ear remains rudimentary.
Inner ear Fgf10 expression has been shown to be downregulated
in both Lmo4 (Deng et al., 2010) and Gata3 (Lillevali et al., 2006)
mouse mutants. However, the relationship of Fgf10 to these genes
has not yet been deﬁned. We have been looking to deﬁne how
inner ear Fgf10 expression is directly regulated, and thereby
integrate the control of Fgf10 into the molecular programme of
inner ear development. Previous studies on Fgf10 regulation had
separated regulatory regions governing limb expression (Sasak
et al., 2002) from regions regulating some aspects of inner ear
expression (Ohuchi et al., 2005). This latter study indicated that
the cis-acting DNA regions controlling early inner ear expression
are all localised within 7 kb of the transcriptional start site,
thereby delimiting this region through which the upstream
regulators directly interact to control otocyst expression. In this
study we take a transgenic mouse approach to deﬁne a minimal
enhancer that controls otocyst expression of Fgf10. Further, we
show that the transcription factor Gata3 is a direct upstream
regulator of Fgf10 that activates inner ear transcription through one
of three Gata3 binding sites. We also show that Fgf10 expression is
subject to control through retinoic acid (RA) signalling, and reveal
that administration of additional RA leads to down-regulation and/
or dorsal displacement of Fgf10 expression.Materials and methods
Generation of transgenic mice
Transgenic mice were generated by pronuclear microinjection
of linearised DNA constructs into pronuclei of F2 eggs produced
by superovulation of 28–38 day old F1(CBAxC57Bl/6) females
crossed with F1 stud males as described in Hogan et al. (1994).
Injected embryos were transferred to pseudopregnant F1(CBAx-
C57Bl/6) females. Founder transgenic embryos were either sacri-
ﬁced during gestation or left to go to term to generate stable
reporter lines for subsequent analysis. Genotyping for the pre-
sence of the reporter transgene was by using internal primers
directed against the ZsGreen ﬂuorescent reporter cassette using
yolk sacs (transient embryo analysis) or ear notches as the tissue
source for DNA extraction. Primers used for genotyping using PCR
were: 50-GGAGATGACCATGAAGTACCGCATGG-30 and 50-GCTTGT-
GCTGGATGAAGTGCCAGTC-30 using the following conditions:
951 C for 2 min; (951 C for 30 s, 65.51 C for 30 s, 721 C for 60 s)
for 30 cycles; 721 C for 2 min. The numbers of transgenic mice/
embryos analysed as founders are detailed in Fig. 2.
Administration of retinoic acid
Exogenous all trans retinoic acid was administered using a
novel non-invasive technique we have recently developed (Cadot
et al., 2012). Retinoic acid was mixed with Dr Oetkers brand
writing icing sugar and administered to transgenic pregnant mice,
at a dose of 25 mg/kg at either 7.75 dpc or 8.5 dpc gestation
stages, with analysis carried out at 9.5 dpc.
In situ hybridisation
In situ hybridisation was carried out according to standard
methods. For in situ hybridisation probes, cDNA fragments were
ampliﬁed using Phusion DNA polymerase (New England Biolabs)
in hi-ﬁdelity PCR. For Fgf10, sequence from nucleotides 695–1264
corresponding to transcript ENSMUST00000022246 was ampliﬁed.
For Gata3, sequence from nucleotides 233–1099 corresponding to
transcript ENSMUST00000102976 was subcloned into bluescript.
Single-stranded DIG-labelled Fgf10 and Gata3 riboprobes were
prepared using RNA polymerases T7 and T3. Mouse embryos
analysed were both inbred and hybrid embryos from C57Bl6/J and
CBA/J matings. At the appropriate gestational age, pregnant mothers
were humanely sacriﬁced and embryos were dissected, rinsed in
PBS and ﬁxed in 4% paraformaldehyde in PBS on ice for between
30 min and 2 h, with exact timing dependent on embryo age/size.
For wholemount in situ hybridizations, embryos were subsequently
rinsed in PBS and dehydrated through a methanol series and stored
at 201 C prior to hybridisation. DIG-labelled probes were used for
in situ hybridisation as previously described (Nonchev and
Maconochie, 1999). For sections, hybridised embryos were
embedded in wax and sectioned at 15 mm.
Analysis of ﬂuorescent activity in transgenic mice.
Embryos were ﬁxed in 4% paraformaldehyde, rinsed in PBS and
directly analysed by ﬂuorescent microscopy. Alternatively where
sectioned material was required, following ﬁxation, embryos
were rinsed in PBS and allowed to equilibrate in 30% sucrose in
PBS, transferred to OCT embedding medium and frozen. 14 mm
sections were taken on a Leica CM1900 cryostat. For whole mount
analysis, inner ears were dissected, ﬁxed in 4% paraformaldehyde,
washed in PBS and dehydrated through an increasing ethanol
series and cleared in methyl salicylate.
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Nikon AZ100 stereomicroscope and images captured using either
a Nikon DS-Fi1 or DS-QiMc digital camera. Conventional micro-
scopy was on a Nikon SMZ1500 stereomicroscope using bright
and dark ﬁeld illumination. Analysis at higher magniﬁcation was
on a Nikon Eclipse TE2000-U and Nikon AZ100.
Electrophoretic mobility shift assays (EMSA)
Recombinant GST-tagged full-length GATA3 protein and
partial (103aa–200aa) GATA3 protein (lacking the DNA binding
domain) were obtained from Abnova (Abnova, Taiwan). 30 ng
of protein was incubated with approximately 50,000 cpm
(or approximately 1 ng; speciﬁc activity 5104 cpm/ng) of
[g-32P]-dATP double-stranded oligonucleotide probe at room
temperature for 1 h, in a 10 ml reaction containing: 20 mM Tris,
50 mM KCl, 1 mM dithiothreitol, 1 mM EDTA, 10 mg bovine serum
albumin (BSA) and 5% sucrose. DNA-protein complexes were
resolved on 8% polyacrylamide gels (acrylamide/bis-acrylamide
29:1) in 0.5xTBE buffer (45 mM Tris–HCl, 45 mM boric acid, 1 mM
EDTA) at 200 V for 35 min. Gels were ﬁxed for 15 min in 10%
acetic acid, 20% methanol solution, dried, exposed to a phosphoi-
mager screen and analysed using a Storm phosphoimager and the
ImageQuant program (Amersham Biosciences).
Oligonucleotides for the three Gata3 binding sites tested were
as follows (only one strand is shown for brevity, but the
complementary oligonucleotide strand was also synthesised):Fgf10 Gata3.1 FOR 50-GACTAATATCACTGGATAGGC-30
Fgf10 Gata3.2 FOR 50-CCTCATTACAGAGATATAATCTAC-30
Fgf10 Gata3.3 FOR 50-GTGATTCAAATCTATTGGG-30Cloning the upstream Fgf10 genomic region
Primers were designed to amplify a fragment larger than the
3-1 fragment (described in Ohuchi et al. (2005)) that supports
limited otic expression. Using the primers Fgf10 3f (50-CAGAGAG-
CATAGCTACTAAGGCATCTG-30) and Fgf10 3r (50-GCTGTGA-
TGTTCGTCACGTTGTTG-30) in hi-ﬁdelity PCR with Phusion DNA
polymerase (NEB) and the following conditions: 1981 C for
1 min; 30981 C for 15 s, 631 C for 30 s, 721 C for 105 s;
1721 C for 5 min, a 1400 bp fragment was ampliﬁed. This
fragment was cloned into pbluescript SK and the sequence
veriﬁed. Finally the Fgf10 test sequence was cloned into a
reporter plasmid constructed by combining a b-globin minimal
promoter subcloned in front of the promoterless ZsGreen vector
obtained from Clontech.
Site-directed mutagenesis
The following primers were used for site-directed mutagenesis
of the three Gata3 binding sites, numerically ordered in increasing
distance from the transcriptional start site:Gata3-1: 50-TACATTCATACATTTATGTTAGTGATATCGGGA
GAGATTGGATTCCGT-30.
Gata3-2: 50-GAGAATGATTCAGGCCTGATTAAGCTTTACATT
CATACATTTATGTTAGTG-30
Gata3-3: 50-CTCTTTCTTTCAATAAAGATTTAGAATTCGATA
GGCTTAGGCCATAGAA-30The above primers were used to mutagenise the individual and
combined sites using the Quickchange and Quickchange-Multi
site-directed mutagenesis kits (Stratagene) with the Fgf10 enhan-
cer cloned above as template. Mutant enhancer sequences wereveriﬁed by sequence analysis and subsequently cloned into the b-
globin minimal promoter-ZsGreen reporter plasmid for trans-
genic analysis.
DNA sequence analysis
DNA sequences were obtained from the publically available
databases www.ensembl.org and www.ncbi.nlm.nih.gov, with
annotation and programmes available at these sites. Analysis of
DNA sequence for potential transcription factor binding sites was
using Matinspector (Quandt et al., 1995) available at www.
genomatix.de.Results
Delimiting an enhancer controlling otic expression of Fgf10
The expression pattern of Fgf10 in the developing inner ear has
been well documented by a number of laboratories previously
(Alvarez et al., 2003; Pauley et al., 2003; Urness et al., 2011;
Wright and Mansour, 2003) and so here we brieﬂy present the
details of the initiation of expression that an inner ear Fgf10
enhancer needs to control. Fgf10 expression in the mouse otic
epithelium is ﬁrst initiated around 8.75 dpc (Fig 1A), where
expression is ﬁrst weakly detected in the anterior region of the
otic placode, just as it begins to invaginate (Fig. 1A). As the
placode sinks below the surface ectoderm to form the otic cup,
Fgf10 expression is more pronounced but still remains restricted
to the anterior region (Fig. 1B). As the otic cup begins to
approach closure around 9.0–9.25 dpc, Fgf10 expression is still
in the anterior otic epithelium but extends ventrally (Fig. 1C,
9.25 dpc). Upon closure to form the otocyst, expression is main-
tained in the anterior otocyst, but lower levels of Fgf10 expression
can be seen throughout the otic epithelium (Fig. 1D, 9.5 dpc). The
ﬁrst major morphogenetic changes of the otocyst are the dorso-
medial extrusion of the endolymphatic duct and dorso-ventral
elongation of the otocyst at 10.0–10.5 dpc, and expression of
Fgf10 remains prominent in the anterior ventral otocyst at these
stages e.g. 10.0 dpc (Fig. 1E). Sections through embryos hybri-
dised against an Fgf10 antisense riboprobe show that the stronger
antero-ventral expression domain throughout early inner ear
development is predominantly medial, located on the neural tube
side of the otocyst (Fig. 1 F).
In order to identify the cis-acting DNA sequences that govern
otic expression of Fgf10, a 7.0 kb region (Fig. 2A), corresponding
to construct F in (Ohuchi et al., 2005) was previously shown to
contain the regulatory sequences that control both inner ear
(Ohuchi et al., 2005) and limb (Sasak et al., 2002) expression of
Fgf10. A smaller 800 bp region within the 7.0 kb enhancer and
located approximately 3.0 kb upstream of the transcriptional start
site was also tested (construct 3-1 in (Ohuchi et al., 2005); Fig. 2A)
and this also controlled some aspects of inner ear expression,
although signiﬁcantly more limited both spatially and temporally.
This 800 bp region did not activate a lacZ reporter gene in
transgenic mice until 11.0 dpc gestational age and, furthermore,
the transgene was activated in more restricted inner ear domains
than the full 7.0 kb region, illustrating that the minimal Fgf10
enhancer controlling inner ear expression includes sequences
beyond this fragment.
To identify the direct upstream regulators of Fgf10, bioinfor-
matics using Matinspector (Quandt et al., 1995) of the 7.0 kb
region upstream of exon I was used to analyse this region, and
this identiﬁed 2194 putative transcription factor binding sites
(data not shown). This included binding sites for transcription factors
that are known to be active in the early developing inner ear. Of
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Fig. 1. Initiation of Fgf10 mRNA expression in the developing mouse inner ear. Weak expression in the anterior otic placode at 8.75 dpc (A). Expression is upregulated
shortly thereafter as the otic placode sinks to form the otic cup (B), and extends more ventrally in the otic epithelium at 9.0 dpc (C). As the otocyst is formed at 9.5 dpc,
expression is throughout the otic epithelium (D), appearing stronger in the antero-ventral region. At 10.0 dpc, these domains are maintained (E). Coronal sections of Fgf10
hybridised embryos at 9.5 dpc illustrate the strong domain of Fgf10 expression is localised to the anterior-medial wall (F). Scale bar 500 mm.
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the transcription factor Gata3 in this region (Fig. 2A and Table 1 in
Supplementary data). Gata3 is of particular interest as a candidate
direct regulator of Fgf10 since Gata3 mouse mutants display
signiﬁcant developmental abnormalities of the inner ear (Duncan
et al., 2011; Haugas et al., 2012; Karis et al., 2001), and moreover,
Fgf10 expression is downregulated in the Gata3 / mutant
(Lillevali et al., 2006). However the position of Fgf10 in the hierarchy
of targets downstream of Gata3 has not been determined. The
presence of multiple binding sites, including clusters of sites around
3.0 kb and 1.0 kb upstream of the transcriptional start, suggested
Gata3 as a direct upstream regulator of Fgf10 in the developing inner
ear. Given the size of this regulatory region (7.0 kb), binding sites for
many other potential transcription factors are also present, and the
occurrence of the large number of Gata3 sites in this region prompted
us to ﬁrst delimit the minimal enhancer governing inner ear expres-
sion of Fgf10, from its initiation in the inner ear and including all its
early otic domains as detailed in Fig. 1.
The 800 bp region controlling later aspects of inner ear expres-
sion was used as a basis to design a series of ﬂuorescent reporter
constructs containing Fgf10 ﬂanking regions of increasing size.
First a 1.4 kb region was tested (construct 266) that extended the
800 bp region in both 30 and 50 directions (Fig. 2 A, B) and was
used to generate transgenic embryos. This construct was able to
recapitulate the entire endogenous Fgf10 inner ear expression
domain (n¼2/3), including the early domain absent from the
800 bp region. Thus the additional series of reporter constructs
with increasing Fgf10 ﬂanking region were not tested, as the
1.4 kb region delimits the minimal functional inner ear enhancer.
The 1.4 kb minimal enhancer controls the complete endogenous
Fgf10 inner ear expression pattern.
Two independent transgenic reporter lines for the minimal
enhancer were generated and the developmental proﬁles of
reporter expression were compared to one another as well as to
endogenous expression of Fgf10 (Fig. 1 and references citedabove). The ﬁrst few cells positive for reporter expression can
be detected in the early invaginating otic placode (Fig. 3A), and
reporter expression rapidly becomes upregulated and includes
further placodal cells as the placode sinks to form the otic cup
(Fig. 3B), where expression is seen to occupy the anterior region
of the otic epithelium. This corresponds to the endogenous
expression of Fgf10 during its initiation (Fig. 1A–C) illustrating
this enhancer contains the control elements required for the onset
of endogenous expression. As the otic cup approaches closure at
9.25 dpc, expression remains anteriorly localised (Fig. 3C), and a
dorsal wholemount view reveals reporter expression is in the
medial wall of the otocyst (Fig. 3D), as is the case for endogenous
Fgf10 mRNA expression (Fig. 1F). At the early otocyst stage,
reporter expression begins to be activated elsewhere in the otic
epithelium (Fig. 3E, 9.5 dpc), although expression remains stron-
ger in the antero-ventral otocyst. Reporter expression remains
pronounced in the ventral otocyst as the endolymphatic duct
begins to bud (Fig. 3F, 10.0 dpc). The endolymphatic duct is
clearly discernable at 10.5 dpc, and reporter expression remains
prominent in the antero-ventral region, but with a second weaker
area of expression in the posterior vesicle (Fig. 3G). This second
domain of otic expression corresponds to that of endogenous
Fgf10 mRNA (Fig. 1F). Coronal sections through 9.5 dpc embryos
at ventral- (Fig. 3H, I) and mid-otocyst levels (Fig. 3J) illustrate
reporter expression is at higher levels in the medial wall, with
some areas of the lateral wall completely devoid of reporter
activity; in general reporter expression appears lowest in
posterior-lateral regions of the otic epithelium. The ventral
sections (Fig. 3H, I) also illustrate the initial migration of isolated
neuroblasts from the anterior ventral wall of the otocyst to
populate the vestibulo-acoustic ganglion, positioned just anterior
to the otocyst (arrowheads, Fig. 3H, I). This migration of Fgf10
expressing neuroblasts becomes clearer in sections at 10.5 dpc
after more extensive migration of FGF10 expressing cells has
occurred; in embryo sections through the ventral otocyst (Fig. 3K)
Fgf10 positive cells are abundant in the developing vestibulo-
acoustic ganglion (VIIIth cranial ganglion), in addition to the
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Fig. 2. Schematic of the Fgf10 upstream region and constructs tested. A. Overview of the location of fragments previously tested in (Ohuchi et al., 2005) and highlighted
with an asterix, and the location of the ten putative Gata3 binding sites in the 7.0 kb region that controls endogenous Fgf10 inner ear expression. (B) Constructs generated
and tested in this report. Black ﬁlled box represents wild-type and red-cross box mutated Gata3 binding sites. Gata3 sites numbered consecutively moving away from the
promoter. Table to the right summarises presence or absence of inner ear expression þ/ (column Exp), with numbers of expressing embryos/transgenic embryos
detailed in the column labelled Tg. Pertinent restriction sites indicated above.
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VIIIth ganglion is absent as is reporter expression outside the otic
epithelium, but expression in the medial wall as well as two more
patches of reporter expression are evident at anterior and poster-
ior locations (Fig. 3L), that likely correspond to the developing
cristae (see below). In a second independently generated trans-
genic line, an additional area of early reporter expression was
noted. In this second line, transgene integration lead to weaker
expression in the developing inner ear, although clearly evident in
the ventral otocyst at 9.5 dpc (Fig. 3N), and transverse sections
reveal expression in the ventral wall as well as the developing
vestibulo-acoustic ganglion (Fig. 3O). However for this line,
expression was also detected speciﬁcally in developing hindbrain
rhombomere 4, being initiated around 8.75 dpc (Fig. 3M) and
upregulated by 9.0 dpc, and clearly evident in the ventral neural
tube (Fig. 3O). A dorsal view at 9.5 dpc shows strong rhombomere
4 reporter activity, just anterior to otocyst expression (Fig. 3P),
with the otocyst developing alongside rhombomeres 5 and 6. This
hindbrain expression is an endogenous area of Fgf10 expression
(Alvarez et al., 2003) and indicates elements controlling this
region of endogenous expression are also present in the minimal
otic enhancer described here.
We also followed reporter expression during later stages of
inner ear development, as although the smaller 800 bp Fgf10
genomic fragment was shown to initiate reporter expression at
E11.0 (Ohuchi et al., 2005), additional aspects of endogenous
inner ear expression were not under the control of this regulatory
region, and we wanted to investigate whether the minimalenhancer described here also governs activity of these missing
domains. At 11.5 dpc, reporter transgene activity was still clearly
visible in the inner ear in whole mount embryos as three
prominent patches of expression (Fig. 4A), corresponding to the
developing cristae, together with more ventral expression that
could not be as clearly visualised through the overlying tissue
layers. At 13.5 dpc, inner ears were dissected away from embryos,
and reporter expression was now very evidently localised to all
six sensory patches; in the three cristae, the utricular and saccular
maculae as well as the sensory epithelium of the developing
cochlea (Fig. 4B). Sections through the 13.5 dpc inner ear at
different levels (Fig. 4C) conﬁrmed expression within the sensory
patch present in the crista (Fig. 4D), in the maculae (Fig. 4E, F) as
well as throughout the sensory epithelium of the cochlea (Fig. 4F,
G). Furthermore reporter expression was also evident in cells in
the spiral ganglion (Fig. 4F, G) and the vestibular ganglion
(Fig. 4E), consistent with the earlier expression seen in delami-
nating neuroblasts in the otocyst. At 17.5 dpc, terminal differ-
entiation of future sensory hair cells begins. Fgf10 reporter
expression was seen in all developing sensory patches, the spiral
and vestibular ganglion in whole mount ears (data not shown)
and these areas of expression are still evident at P0 (Fig. 4H), with
prominent reporter expression in the three cristae, two maculae
and the coiled cochlea (Fig. 4H). Sections of P0 heads of transgenic
mice showed reporter expression localised to the sensory epithe-
lia of the cristae (Fig. 4I) and the maculae (Fig. 4I, J) and in the
organ of Corti, reporter expression was present in the greater
epithelial ridge, but absent in the adjacent lesser epithelial ridge
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Fig. 3. Early reporter activity of the 1.4 kb Fgf10 enhancer in the developing inner ear. Reporter activity ﬁrst detected around 8.75 dpc (A) and is rapidly upregulated as the
placode sinks to form the early otic cup (B) and is maintained in this region at 9.25 dpc as the otic cup approaches closure (C). (A–C) anterior is to the left. Dorsal
wholemount view illustrates reporter activity in the anterior-medial wall (9.25 dpc, D). (E–G; anterior to the left). At the early otocyst stage, expression is also detected
elsewhere in the otic epithelium (9.5 dpc, E) albeit weaker than the antero-ventral domain, and is maintained at 10.0 dpc (F). Strong anterior and weaker posterior domains
of expression at 10.5 dpc (G). Coronal sections at ventral (H, I) and mid-otocyst (J) planes through the 9.5 dpc otocyst illustrate high levels of activity in the medial and
anterior walls. Isolated cells leaving the otic epithelium highlighted by arrowhead. Ventral (K) and mid-otocyst (L) sections through the 10.5 dpc otocyst reveal reporter
activity in the medial wall and two patches in the anterior and posterior wall (small arrowheads), as well as post migratory neuroblasts postitive for reporter activity in the
VIIIth ganglion (K). A second independent transgenic line shows the same expression domains although weaker, with additional reporter activity detected in the
developing hindbrain. Hindbrain expression ﬁrst detected at 8.75 dpc (M, anterior-top), and is strongly upregulated in rhombomere 4 by 9.5 dpc (P, anterior-top). Reporter
activity is detected in the ventral otocyst at 9.5 dpc (N) and transverse sections reveal reporter activity in the VIII ganglion (10.0 dpc, O). ba-branchial arch; oc-otic cup;
ov-otocyst, ed-endolymphatic duct, m-medial, l-lateral. Scale bar 500 mm unless otherwise indicated.
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spiral ganglion (Fig. 4K) as at earlier stages.
These later patterns of reporter expression recapitulate those
of endogenous Fgf10 mRNA in the inner ear (Pauley et al., 2003),
and together with the analysis of early reporter expression above
(Fig. 3) illustrates the 1.4 kb minimal enhancer contains the
regulatory regions that control the onset and maintenance of
embryonic Fgf10 expression in the developing mouse inner ear
throughout gestation.
Expression analysis supports Gata3 as a candidate direct upstream
regulator of Fgf10
The deﬁnition of the minimal enhancer controlling Fgf10 inner
ear expression to 1.4 kb of ﬂanking Fgf10 sequence was next
readdressed with respect to the bioinformatic analysis for puta-
tive transcription factor binding sites, since this smaller regula-
tory region will considerably reduce the number of potential
candidates. Interestingly, one of the two clusters of Gata3 bindingsites highlighted earlier in the 7.0 kb region is located within this
regulatory region (Fig. 2A). Since Gata3 has previously been
reported to be expressed in the developing inner ear (Lawoko-
Kerali et al., 2002; Nardelli et al., 1999; Pauley et al., 2003), we
next investigated the details of onset and early otic expression of
Gata3 mRNA using whole mount in situ hybridisation. Gata3
expression is initiated in the otic placode at 8.75–9.0 dpc, with
expression throughout the invaginating placode (Fig. 5A), and as
the placode sinks to form the otic cup (Fig. 5B), Gata3 mRNA
expression is located throughout the otic epithelium (dorsal view,
Fig. 5C), but is considerably weaker in the lateral wall. Gata3
expression can be seen throughout the closing otic cup (Fig. 5D)
although again weaker in lateral regions, and throughout the
early otocyst (9.5 dpc, Fig. 5E). Gata3 expression is also evident in
the developing vestibuloacoustic ganglion (10.5 dpc, Fig. 5F)
located just anterior to the otocyst. Sections through embryos
hybridised against Gata3 riboprobes illustrate extensive expres-
sion thoughout the otic epithelium (Fig. 5G). Thus through early
development of the inner ear, the expression pattern of Gata3
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Fig. 4. The 1.4 kb Fgf10 minimal enhancer controls expression in all developing sensory patches through late gestation. Wholemount inner ears at 11.5 dpc reveal reporter
expression in two anterior and one posterior equatorial patch corresponding to the separating cristae, as well as in ventral regions (A). Wholemount ears at 13.5 dpc reveal
reporter activity in all three cristae (cr), in the utricular and saccular maculae (mac) and in the developing cochlea (co, B). Sections taken as illustrated in (C) of 13.5 dpc
heads detail expression in the crista (D), macula (E and F), cochlea (F, G) as well as in vestibular (vg) (E) and spiral (sg) ganglia (F,G). These domains are maintained in P0
wholemount ears (H). Sections taken at P0 illustrate reporter activity remains robust in maculae, cristae and cochlea (I-dorsal, J-mid ear, K-ventral sections). GER—greater
epithelial ridge. Scale bar 500 mm unless otherwise indicated.
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described above.
The Gata3 binding sites in the minimal enhancer are highly conserved
The sequence of the three Gata3 binding sites in the minimal
enhancer was further analysed. Regions of sequence homology
have been shown to exist between upstream regions of chicken,
mouse and human Fgf10 (Ohuchi et al., 2005) (and our unpub-
lished data), and the cluster of these three Gata3 binding sites is
within one of these areas of homology. All putative Gata3 binding
sites in this cluster were found in the corresponding human,
chicken and mouse Fgf10 ﬂanking region. The sequence of Gata3
sites 1 and 2 were found to be completely conserved across all
three species (Fig. 6A), whereas Gata3 site 3 showed more
interspeciﬁc variation, although still represents a potential Gata3
binding site (core similarity 0.88; matrix similarity 0.92; see
Table 1, Supplementary data).
Gata3 protein binds all three sites from the Fgf10 minimal enhancer
but with differing afﬁnity
These motifs remain notional Gata3 binding sites until tested,
so we ﬁrst investigated the ability of GATA3 protein to bind the
three sites, using electrophoretic mobility shift assays (EMSAs).
Oligonucleotides were designed that incorporated either sites 1,2, or 3, and were incubated with full length human GATA3
protein. All oligonucleotides generated a gel-retarded complex
in EMSA (Fig. 6B), although the intensity of the complex gener-
ated varied between sites, reﬂecting differing binding afﬁnity of
the GATA3 protein for each site. These binding assays were
carried out on three separate occasions with identical results. In
these assays, no gel shift was noted in the samples lacking GATA3
full length protein (Fig. 6B). The strongest afﬁnity was seen for
site 2 (þGata3 full prot; Fig. 6B), and weaker complexes of similar
size were noted for Gata3 sites 1 and 3 (þGata3 full prot; Fig. 6B).
We next sought to ensure that the interaction with GATA3
protein was through the DNA binding domain of GATA3 and not
some other association. Therefore the EMSA reactions were
carried out using a truncated GATA3 protein, where the trunca-
tion removes this DNA binding domain. In all three cases, the
truncated GATA3 protein did not lead to any generation of a gel
retarded complex (Fig. 6B; þ lanes Gata3 truncated prot). This
conﬁrms GATA3 protein binds the Gata3 binding sites via its DNA
binding domain.
In order to investigate the speciﬁcity of the interaction, we also
performed competition EMSAs, where increasing amounts of
unlabelled oligonucleotide were incubated along with labelled
oligonucleotides and full length GATA3 protein. In the negative
control without GATA3 protein, no gel retarded complex
was formed (Fig. 6C;  lanes Gata3 prot). Addition of full length
protein generated complexes (Fig. 6C,þ lanes Gata3 prot) and the
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Fig. 5. Early expression of Gata3 mRNA supports its role as a direct upstream regulator of Fgf10. Gata3 otic expression is ﬁrst seen as the otic placode begins to invaginate
at 8.75 dpc (A) and is upregulated as it forms the otic cup (oc) (B). Dorsal views of the otic cup show extensive Gata3 expression in the otic epithelium although absent
from the lateral walls (9.0 dpc, C). Expression is maintained as the otic cup approaches closure (9.25 dpc, D) and is also evident throughout the early otocyst (9.5 dpc, E),
including expression in the antero-ventral domain (arrowhead). At 10.5 dpc, strong Gata3 expression is maintained in the anterior otic epithelium and developing ganglion
(F). Coronal sections at 9.5 dpc illustrate extensive Fgf10 expression in the otic epithelium (G). Scale bar 500 mm.
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complete loss (site 1) or dramatic reduction of the gel retarded
complex for sites 2 and 3 (Fig. 6C; þ 100) Comp oligo.
Functional analysis of the Gata3 binding sites in vivo
We next sought to address whether the Gata3 sites present in
the minimal Fgf10 enhancer have any functional signiﬁcance.
Mutations were generated in all three potential Gata3 binding
sites, and the triple mutant enhancer was then cloned in front of
the ZsGreen ﬂuorescent reporter gene used earlier. This construct
(construct 265, Fig. 2B) was used to generate transgenic embryos.
These mutations abolished reporter expression in the otic
vesicle and associated VIIIth ganglion (n¼0/3, Fig. 7A) in embryos
harvested at 10.5 dpc, indicating a requirement for these Gata3
binding sites for reporter activity.
We ﬁnally wanted to address the individual or combinatorial
requirements of the different Gata3 sites for controlling Fgf10
inner ear expression, and so prepared single and double combina-
tions of mutations for all three sites, and cloned these mutant
enhancers into the ﬂuorescent reporter. We ﬁrst analysed the
in vivo function of the single Gata3 mutant sites. Analysis of
transgenic embryos at 10.5 dpc harbouring a mutation in Gata3
site 1 (construct 271; Fig. 7B, B0) showed there was no effect on
reporter expression (n¼2/2). Nor did mutation in Gata3 site 3 lead
to loss of reporter expression (construct 273; n¼3/4, Fig. 7C, C0).
However mutation of Gata3 site 2 alone lead to a complete loss of
reporter expression in transgenic embryos at 10.5 dpc, even after
repeated injections (construct 272, n¼0/7, data not shown). To
address any potential combinatorial requirements of sites 1 and 3,
reporter transgenes containing combined enhancer mutations in
Gata3 sites 1 and 3 were injected, but this too did not lead to loss
of reporter expression in the otocyst (construct 269; n¼3/5,Fig. 7D–F). Together, these data demonstrate that of the three
Gata3 binding sites, only Gata3 site 2 is essential to control Fgf10
expression during early development of the inner ear.
Fgf10 expression is dynamically downregulated by retinoic acid (RA)
during the period of hindbrain patterning.
The generation of a stable reporter line for Fgf10 allowed us to
investigate the input of other regulatory molecules on Fgf10
expression, such as the developmentally critical signalling mole-
cule retinoic acid (RA). We recently showed that otocyst expres-
sion of the related ligand Fgf3 is subject to regulation by RA. Fgf3
is downregulated in a dose dependent manner following admin-
istration of exogenous RA, where a dose of 25 mg/kg is able to
extinguish Fgf3 expression (Cadot et al., 2012).
To investigate any effects on Fgf10 expression by RA, we used a
novel alternative method of feeding RA to pregnant transgenic
females carrying the minimal Fgf10 reporter. 25 mg/kg RA was
administered at 7.75 dpc, during hindbrain patterning (Fig. 8B–F),
and two major changes in the Fgf10 expression pattern were
detected when transgenic embryos were analysed at 9.5 dpc. First
there was a change in the spatial localisation of reporter expres-
sion, with reporter activity shifted dorsally in the otocyst (n¼9/
21, Fig. 8B, C; compare to control Fig. 8A). Secondly, the antero-
ventral expression domain of the Fgf10 reporter was downregu-
lated in the otocyst (n¼13/21); expression was either absent in
this region (Fig. 8B–D) or not elevated above otic epithelial levels
elsewhere (Fig. 8F). Occasionally embryos were detected that
retained an anterior patch of reporter expression (n¼2/21;
Fig. 8E), although this too appeared to be somewhat dorsally
shifted. Intriguingly we also noticed reproducible activation of the
Fgf10 reporter transgene in anterior regions of the embryo, in the
forebrain (n¼5/21; Fig. 8B–D).
Fig. 6. Fgf10 Gata3 binding sites are highly conserved and bind Gata3 protein
in EMSA. (A) Sequence comparison of the mouse 1.4 kb enhancer identiﬁes
conserved regions from human, mouse and chick that include Gata3 binding
sites. Sequence alignments of the conserved Gata3 binding sites are shown.
(B) EMSA analysis of Gata3 binding sites shows full length protein is able to form
gel retarded complexes with all three sites but with differing afﬁnities. These
complexes are not formed when using a truncated form of the protein that lacks
the DNA binding domain. (C) Competition EMSA of the Gata3 binding sites with
excess unlabelled oligonucleotides (x100) either reduces or abolishes the gel
retarded complex formed with the three Gata3 sites. Gel retarded complexes are
indicated by arrows in (B,C).
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females after the hindbrain was patterned (8.5 dpc), and analysed
embryos again at 9.5 dpc. We did not detect any dorsalisation of
reporter activity in all the embryos analysed (n¼13). However in
a number of embryos (n¼4/13), there was some downregulation
of the antero-ventral domain of reporter activity (Fig. 8H, I),
whereas in most embryos this domain appeared largely unaltered
(n¼9/13; Fig. 8G). In addition, the general epithelial activity inthe otocyst also appeared unaltered (n¼13/13). This illustrates
that exogenous RA has the effect to downregulate and change the
spatial pattern of Fgf10 expression when applied during the
period the hindbrain is being patterned, and also differentially
affects expression in the anterior otocyst when administered after
hindbrain patterning.Discussion
Gata3 is a direct upstream regulator of Fgf10 in the developing inner
ear.
In this report we delimit the enhancer that controls inner ear
expression of Fgf10, shown by the ability of the enhancer to
confer activity on a reporter transgene. Detailed analysis of
reporter activity reveals that the transgene faithfully recapitulates
endogenous Fgf10 expression, from the onset of expression in the
inner ear through to neonatal stages. We show the presence of a
cluster of Gata3 binding sites in this enhancer, and demonstrate
that GATA3 protein binds these sites in vitro through its DNA
binding domain. Functional testing of these sites however shows
that only one site, Gata3 site 2, is absolutely required for reporter
expression. These data indicate that Fgf10 is a direct target for
Gata3, and the direct interaction of Gata3 through site 2 is
required to activate and maintain expression in the otocyst.
Molecular mechanisms of Fgf10 regulation in the inner ear
Bioinformatic analysis of the 7.0 kb upstream region of Fgf10
revealed the presence of ten Gata3 binding sites, suggesting some
sub-organisation of sites in two clusters of binding sites, but the
functional analysis here shows only a single Gata3 site is
necessary for Fgf10 expression. However this single Gata3 site is
not sufﬁcient for otocyst expression since the 800 bp region
previously tested (Ohuchi et al., 2005) was unable to drive
reporter expression in the early otocyst. This indicates other
inputs in addition to Gata3 and its cognate binding site are
required for the initiation of Fgf10 expression in the inner ear.
By reducing the DNA region analysed to functionally veriﬁed
sequence in a minimal 1.4 kb enhancer, we were able to reduce
the candidate Gata3 binding sites to just three, and moreover
sequence analysis revealed two of the three sites were completely
conserved between species. The prediction was that this con-
servation likely reﬂected a combinatorial requirement for sites
1 and 2. However the EMSA assays showed that although all three
sites bound GATA3 protein, site 2 showed particularly high
afﬁnity, in contrast to low afﬁnity interactions with sites 1 and
3, even though one of these sites being completely conserved
across species as detailed above. The functional testing of differ-
ent mutant sites corroborated these in vitro binding data, with
only the strong site 2 being absolutely necessary for reporter
activity. However it is important to remember this analysis does
not rule out a function for the other Gata3 binding sites in Fgf10
regulation, merely that they are not necessary for reporter
activity. Nevertheless the relatively poor afﬁnity for binding the
GATA3 protein does suggest they are probably not likely involved
in executing the Gata3 control of Fgf10 expression. This is some-
what curious given the highly conserved sequence context of site
1. Perhaps this site binds another transcription factor, for example
GATA2. Gata2 expression is not initiated in the otocyst until
9.5 dpc (Lillevali et al., 2004), and analysis of Gata2 null alleles did
not reveal any inner ear phenotypes up to the time of embryo
lethality at 10.5 dpc (Tsai et al., 1994). Perhaps then Gata2 could
provide additional support for driving Fgf10 expression later
during development through this conserved site 1, although site
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Fig. 7. Gata3 site 2 is essential for in vivo expression of Fgf10. Mutation of all three Gata3 sites lead to loss of activity of the Fgf10 enhancer (A). Mutation in Gata3 site 1
(B) and site 3 (C) did not lead to loss of expression, whereas mutation in site 2 lead to complete loss of reporter activity (not shown). Combined mutations in sites 1 and
3 similarly do not lead to loss of activity (D–F). All embryos analysed at 10.5 dpc, and oriented anterior to the right except C and C0 . B0 and C are bright ﬁeld images
corresponding to panels B,C0 . In C two transgenic embryos are shown, one showing expression and one without.
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might suggest a complex interplay of Gata2 and Gata3 controlling
Fgf10 inner ear expression during later stages of inner ear
development, and indeed Gata2 has been shown to have non-
redundant functions during later stages of development in the
inner ear. Conditional inactivation of Gata2 was used to overcome
the lethality of null mutants and revealed a role for this tran-
scription factor in canal morphogenesis and removal of periotic
mesenchyme (Haugas et al., 2010). Arguing against a role for
Gata2 in the regulation of Fgf10 is the absence of elements of the
Fgf10 phenotype in Gata2 mutants, although it may well require a
different strategy to reveal this, for example by preparing condi-
tional double mutant alleles (Gata3/; Gata2/ deleted in
the inner ear) to uncover redundant functions of Gata2/3achieved through directly regulating Fgf10. It would also be
interesting to examine Fgf10 expression in Gata2 mutants,
although if there is no change, this may be because of redundant
functions that the conditional double mutant will address.
The identiﬁcation of clustered binding sites may well increase
the probability of identifying functionally relevant sites via
bioinformatics (Gotea et al., 2010; Lifanov et al., 2003), but in
this case only one of the three binding sites in the ‘‘cluster’’ was
shown to be necessary for expression. The EMSA turned out to
have strong predictive value for the functionality of site 2. An
alternative explanation for the failure of generating robust gel
retarded complexes with sites 1 and 3 could be that additional
cofactors are required along with GATA3 for strong binding to
sites 1 and 3, but nevertheless the functional testing in this report
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Fig. 8. Response of Fgf10 to retinoic acid. Using the Fgf10 reporter line, the response to 25 mg/kg retinoic acid administered during hindbrain patterning (7.75 dpc; B–F)
and after hindbrain patterning (8.5 dpc, G–I) was analysed in embryos at 9.5 dpc. Embryos oriented anterior to left. (A) Control embryos fed pellet without retinoic acid. (B,
C) embryos showing dorsalisation of reporter activity and loss of anterior expression; (D, F) embryos exhibiting loss of anterior activity and (E) rarer embryos showing little
discernable change in reporter expression. Following RA administration at 8.5 dpc, transgene reporter activity at 9.5 dpc is either unchanged (G) or the antero-ventral
domain downregulated to varying extents (H, I). C0 , F0and I0 bright ﬁeld images corresponding to panels C, F and I. ov-otocyst.
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Thus it seems clear that although binding can be achieved with
GATA3 protein in vitro for sites 1 and 3, albeit it with low afﬁnity,
a functional analysis is absolutely required to determine whether
they are required in vivo. To conclude, even a combination of high
scores using bioinformatics, a complete conservation of the
sequence of sites across three vertebrate species and the ability
to bind GATA3 protein in vitro do not necessarily indicate the
functional relevance of a Gata3 binding site.
The nature of the additional factors required along with Gata3
to initiate Fgf10 expression in the inner ear remains unknown.
Matinspector analysis of the 1.4 kb enhancer deﬁnes 499 indivi-
dual binding sites, including sites for transcription factors that
have been shown to play important roles in early inner ear
development such as Six1, Pax2 and others. The discussion above
indicates that the presence of binding sites alone is only a ﬁrst
step in the identiﬁcation of any functional link, since consensus
sequences for binding sites are likely to occur by chance randomly
throughout the genome that may have no functional signiﬁcance.
However the presence of these sites in a functionally veriﬁed
enhancer at least puts these sites into a functional context. It will
require similar biochemical and in vivo approaches to deﬁne what
cofactors are required to co-operate with Gata3 to initiate Fgf10
expression. Indeed it may well be that binding sites for the
cofactors have not yet been deﬁned, and thus are not present in
the transcription factor databases, in which case an extensive
deletion analysis of the minimal enhancer may also be necessary.
In one of the independent lines analysed, reporter expression
in the hindbrain was noted. Fgf10 expression is also present in the
early hindbrain (Alvarez et al., 2003), and moreover Gata3 is
expressed in rhombomere 4 (Nardelli et al., 1999; Pata et al.,
1999). This suggests that there could be a related mechanism
utilising Gata3 in both these embryonic contexts. However the
position dependent effects of this hindbrain activity of the
transgene suggests there are clear differences in the molecular
mechanisms underlying regulation of inner ear and hindbrain
Fgf10 expression, and likely reﬂect the interaction of Gata3 with
different cofactors in the two contexts, where the binding sites for
hindbrain cofactors may be absent or under represented in theminimal inner ear enhancer deﬁned here. There does of course
also remain the possibility of ‘‘fortuitous’’ integration of the
reporter transgene into another gene expressed in the developing
hindbrain, with the reporter scoring activity of this unrelated
gene. However we favour the former hypothesis given endogen-
ous Fgf10 expression here and more than one integration event
leading to hindbrain expression. We did not pursue the hindbrain
regulation further as the focus of this study was on inner ear
regulation of Fgf10, but does suggest that a Gata3 input into Fgf10
regulation may well be conserved in the hindbrain as well.
Finally it is important to remember that the hindbrain and
inner ear are only two domains of the overall pattern of endo-
genous Fgf10 expression. To control the entire Fgf10 expression
pattern additional enhancers are necessary. A limb enhancer has
previously been reported (Sasak et al., 2002), and Fgf10 expres-
sion between 8.25–10.5 dpc in pharyngeal mesoderm that gives
rise to part of the developing heart tube (Kelly et al., 2001), a
domain not identiﬁed in the Fgf10-enhancer reporter expression
analysis here, suggests this activity is controlled by a different
enhancer as well. Indeed this heart enhancer has recently been
localised to intron1 and is under the control of Isl1 (Golzio et al.,
2012). Another major area of Fgf10 expression and function is the
developing lung, and the presence of lung-related transcription
factor binding sites 3 kb downstream of the Fgf10-ATG may
underlie the presence of a lung enhancer (El Agha et al., 2012),
although the ability of this region to control lung expression has
yet to be demonstrated. Thus a picture of multiple enhancers
controlling different domains of Fgf10 expression is emerging,
that together are responsible for controlling the complete Fgf10
expression pattern.
Differences and similarities in retinoic acid control of Fgf10 and Fgf3
in the inner ear.
We recently demonstrated that following administration of
exogenous RA during hindbrain patterning (7.75 dpc), Fgf3
expression is downregulated in the otocyst in a dose-dependent
manner (Cadot et al., 2012). Prior to complete downregulation,
there is a spatial change in the pattern of Fgf3 expression, with a
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increasing RA dose. The response of Fgf10 shows similarities and
differences to Fgf3. When RA is administered at 7.75 dpc, Fgf10
expression becomes more dorsally localised in the otocyst, and
the antero-ventral domain appears to be lost or downregulated in
most embryos. Thus whilst both Fgf3 and Fgf10 expression are
downregulated and exhibit changes in otocyst localisation, the
precise spatial changes are different.
Administration of RA at 8.5 dpc after hindbrain patterning, i.e.
at a time when retinoic acid no longer changes the identity of the
posterior hindbrain (Glover et al., 2006; Wood et al., 1994), did
not lead to a posterior shift of Fgf3, but rather, only to increasing
downregulation of the antero-ventral domain with increasing
levels of RA (Cadot et al., 2012). In a similar manner, there was
no spatial shift in the otocyst domain of Fgf10 expression.
However, there were differences in the extent and incidence of
the downregulation observed. Whereas 25 mg/kg RA lead to
490% embryos showing downregulation of Fgf3 expression
(Cadot et al., 2012), only 30% Fgf10 reporter embryos demon-
strated some downregulation. For both genes, the antero-ventral
domain is downregulated, with the Fgf10 otic epithelial activity
outside this domain remaining unaffected.
Thus plasticity of otocyst patterning is very evident at
7.75 dpc, since both Fgf3 and Fgf10 domains can be relocated in
the otocyst although to different locations, whereas administra-
tion at 8.5 dpc merely downregulates the antero-ventral domains.
Not only does this represent a clear difference in the regulatory
response of the two ligands to RA, but also demonstrates the
7.75 dpc inner ear is able to reprogramme its spatial gene
expression proﬁle. Whilst we do not know when the different
otic axes are determined in the mouse, otocyst transplantation
experiments in the chick have shown that Pax2 expression can be
reprogrammed to its new axis following rotations performed as
late as the otocyst stage (Hutson et al., 1999). Furthermore,
retinoic acid appears to be responsible in part for the AP polarity
of the otocyst (Bok et al., 2011), with endogenous retinoic acid
sources present at both anterior and posterior poles of the otocyst
(Cadot et al., 2012). One major retinoic acid source in the otic
region is the presomitic/early somitic mesoderm (Romand et al.,
2006a) located posteriorly to the developing inner ear, and a
second source is the anterior/dorsal otic epithelium itself
(Romand et al., 2006b). Administration of excess retinoic acid
leads to increases in the amounts of RA at both anterior and
posterior poles and affects the spatial organisation of RA respon-
sive genes such as the FGFs during hindbrain patterning.
Fgf10 downregulation with high doses of RA, conﬁrms our
earlier studies using RT-PCR to analyse otocyst mRNA (Frenz
et al., 2010). What the in vivo study here clearly shows is that it is
the antero-ventral domain of Fgf10 expression that is down-
regulated or lost with exogenous RA administration, in that
population of otic cells that will give rise to the vestibulo-
acoustic ganglion as well as sensory hair cells.
The subtly different spatial responses of Fgf3 and Fgf10 to RA
suggests differences in the regulation of the two ligands. This
might also reﬂect differences in their downstream functions
within the otic epithelium that have yet to be fully deﬁned with
respect to one another, since the potential of Fgf3/10 redundancy
within the otic epithelium and the associated vetibuloacoustic
ganglion has not yet been reported. The major spatial reprogram-
ming of Fgf3/10 expression to exogenous RA occurs during
hindbrain patterning. Whether this response is direct through
the FGF otic enhancers or secondary and due to alterations in
hindbrain patterning will be interesting to deﬁne. In addition this
study raises the possibility that some of the changes in otic Fgf10
expression with RA may be mediated through a mechanism that
may involve the relocalisation of Gata3, although downregulationof Gata3 as the central mechanism is unlikely as Gata3 mRNA
does not appear to be reduced following RA administration (Frenz
et al., 2010).Acknowledgements
We thank the Wellcome Trust [WT079094] and Deafness
Research, UK (Grants to MKM) and the National Organisation
for Hearing Research, USA (Grant to DF.) for supporting this work.
We thank Professor Guy Richardson for critical reading of the
manuscript and we are grateful to Vince Edwards for excellent
animal husbandry and ensuring optimal day to day care and
welfare.Appendix A. Supplementary information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.ydbio.2012.11.028.References
Adamska, M., Herbrand, H., Adamski, M., Kruger, M., Braun, T., Bober, E., 2001. FGFs
control the patterning of the inner ear but are not able to induce the full ear
program. Mech. Dev. 109, 303–313.
Alvarez, Y., Alonso, M., Vendrell, V., Zelarayan, L., Chamero, P., Theil, T., Bosl, M.,
Kato, S., Maconochie, M., Riethmacher, D., Schimmang, T., 2003. Requirements
for FGF-3 and FGF-10 during inner ear formation. Development 130,
6329–6338.
Bok, J., Raft, S., Kong, K.A., Koo, S.K., Drager, U.C., Wu, D.K., 2011. Transient retinoic
acid signaling confers anterior-posterior polarity to the inner ear. Proc. Natl.
Acad. Sci. USA 108, 161–166.
Cadot, S., Frenz, D., Maconochie, M., 2012. A novel method for retinoic acid
administration reveals differential and dose-dependent downregulation of
Fgf3 in the developing inner ear and anterior CNS. Dev. Dyn. 241, 741–758.
Carnicero, E., Garrido, J.J., Alonso, M.T., Schimmang, T., 2001. Roles of ﬁbroblast
growth factor 2 during innervation of the avian inner ear. J. Neurochem. 77,
786–795.
Chang, W., Brigande, J.V., Fekete, D.M., Wu, D.K., 2004. The development of
semicircular canals in the inner ear: role of FGFs in sensory cristae. Develop-
ment 131, 4201–4211.
Deng, M., Pan, L., Xie, X., Gan, L., 2010. Requirement for Lmo4 in the vestibular
morphogenesis of mouse inner ear. Dev. Biol. 338, 38–49.
Dominguez-Frutos, E., Vendrell, V., Alvarez, Y., Zelarayan, L.C., Lopez-Hernandez, I.,
Ros, M., Schimmang, T., 2009. Tissue-speciﬁc requirements for FGF8 during
early inner ear development. Mech. Dev. 126, 873–881.
Duncan, J.S., Lim, K.C., Engel, J.D., Fritzsch, B., 2011. Limited inner ear morphogen-
esis and neurosensory development are possible in the absence of GATA3. Int.
J. Dev. Biol. 55, 297–303.
El Agha, E., Al Alam, D., Carraro, G., MacKenzie, B., Goth, K., De Langhe, S.P.,
Voswinckel, R., Hajihosseini, M.K., Rehan, V.K., Bellusci, S., 2012. Characteriza-
tion of a novel ﬁbroblast growth factor 10 (Fgf10) knock-in mouse line to
target mesenchymal progenitors during embryonic development. PLoS ONE 7,
e38452.
Fantetti, K.N., Fekete, D.M., 2012. Members of the BMP, Shh and FGF morphogen
families promote chicken statoacoustic ganglion neurite outgrowth and
neuron survival in vitro. Dev. Neurobiol. 72, 1213–1228.
Fekete, D.M., 1996. Cell fate speciﬁcation in the inner ear. Curr. Opinion Neurobiol.
6, 533–541.
Fekete, D.M., Wu, D.K., 2002. Revisiting cell fate speciﬁcation in the inner ear. Curr.
Opinion Neurobiol. 12, 35–42.
Frenz, D.A., Liu, W., Cvekl, A., Xie, Q., Wassef, L., Quadro, L., Niederreither, K.,
Maconochie, M., Shanske, A., 2010. Retinoid signaling in inner ear develop-
ment: a ‘‘Goldilocks’’ phenomenon. Am. J. Med. Genet. A 152A, 2947–2961.
Glover, J.C., Renaud, J.S., Rijli, F.M., 2006. Retinoic acid and hindbrain patterning. J.
Neurobiol. 66, 705–725.
Golzio, C., Havis, E., Daubas, P., Nuel, G., Babarit, C., Munnich, A., Vekemans, M.,
Zaffran, S., Lyonnet, S., Etchevers, H.C., 2012. ISL1 directly regulates FGF10
transcription during human cardiac outﬂow formation. PLoS ONE 7, e30677.
Gotea, V., Visel, A., Westlund, J.M., Nobrega, M.A., Pennacchio, L.A., Ovcharenko, I.,
2010. Homotypic clusters of transcription factor binding sites are a key
component of human promoters and enhancers. Genome Res. 20, 565–577.
Hammond, K.L., Whitﬁeld, T.T., 2011. Fgf and Hh signalling act on a symmetrical
pre-pattern to specify anterior and posterior identity in the zebraﬁsh otic
placode and vesicle. Development 138, 3977–3987.
Hans, S., Christison, J., Liu, D., Westerﬁeld, M., 2007. Fgf-dependent otic induction
requires competence provided by Foxi1 and Dlx3b. BMC Dev. Biol. 7, 5.
A. Economou et al. / Developmental Biology 374 (2013) 210–222222Hans, S., Liu, D., Westerﬁeld, M., 2004. Pax8 and Pax2a function synergistically in
otic speciﬁcation, downstream of the Foxi1 and Dlx3b transcription factors.
Development 131, 5091–5102.
Hans, S., Westerﬁeld, M., 2007. Changes in retinoic acid signaling alter otic
patterning. Development 134, 2449–2458.
Hatch, E.P., Noyes, C.A., Wang, X., Wright, T.J., Mansour, S.L., 2007. Fgf3 is required
for dorsal patterning and morphogenesis of the inner ear epithelium. Devel-
opment 134, 3615–3625.
Haugas, M., Lillevali, K., Hakanen, J., Salminen, M., 2010. Gata2 is required for the
development of inner ear semicircular ducts and the surrounding perilym-
phatic space. Dev. Dyn. 239, 2452–2469.
Haugas, M., Lillevali, K., Salminen, M., 2012. Defects in sensory organ morphogen-
esis and generation of cochlear hair cells in Gata3-deﬁcient mouse embryos.
Hear. Res. 283, 151–161.
Hayashi, T., Ray, C.A., Bermingham-McDonogh, O., 2008. Fgf20 is required for sensory
epithelial speciﬁcation in the developing cochlea. J. Neurosci. 28, 5991–5999.
Hogan, B., Beddington, R., Constantini, F., Lacy, E., 1994. Manipulating the Mouse
Embryo. Cold Spring Harbor Laboratory Press, New York.
Hossain, W.A., Zhou, X., Rutledge, A., Baier, C., Morest, D.K., 1996. Basic ﬁbroblast
growth factor affects neuronal migration and differentiation in normotypic
cell cultures from the cochleovestibular ganglion of the chick embryo. Exp.
Neurol. 138, 121–143.
Huh, S.H., Jones, J., Warchol, M.E., Ornitz, D.M., 2012. Differentiation of the lateral
compartment of the cochlea requires a temporally restricted FGF20 signal.
PLoS Biol. 10, e1001231.
Hutson, M.R., Lewis, J.E., Nguyen-Luu, D., Lindberg, K.H., Barald, K.F., 1999. Expression
of Pax2 and patterning of the chick inner ear. J. Neurocytol. 28, 795–807.
Jacques, B.E., Montcouquiol, M.E., Layman, E.M., Lewandoski, M., Kelley, M.W.,
2007. Fgf8 induces pillar cell fate and regulates cellular patterning in the
mammalian cochlea. Development 134, 3021–3029.
Karis, A., Pata, I., van Doornick, J., Grosveld, F., de Zeeuw, C., de Caprona, D.,
Fritzsch, B., 2001. Transcription factor Gata3 alters pathway selection of
olivocochlear neurons and affects morphogenesis of the ear. J. Comp. Neurol.
429, 615–630.
Kelly, R.G., Brown, N.A., Buckingham, M.E., 2001. The arterial pole of the mouse heart
forms from Fgf10-expressing cells in pharyngeal mesoderm. Dev. Cell 1, 435–440.
Kiernan, A.E., Steel, K.P., Fekete, D.M., 2002. Development of the mouse inner ear.
In: Rossant, J., Tam, P. (Eds.), Mouse Development, Patterning, Morphogenesis
and Organogenesis. Academic Press, London, pp. 539–566.
Ladher, R.K., Wright, T.J., Moon, A., Mansour, S.L., Schoenwolf, G.C., 2005. FGF8
initiates inner ear induction in chick and mouse. Genes Dev. 19, 603–613.
Lawoko-Kerali, G., Rivolta, M., Holley, M., 2002. Expression of the transcription
factors GATA3 and Pax2 during development of the mammalian inner ear. J.
Comp. Neurol. 442, 378–391.
Lifanov, A.P., Makeev, V.J., Nazina, A.G., Papatsenko, D.A., 2003. Homotypic
regulatory clusters in Drosophila. Genome Res. 13, 579–588.
Lillevali, K., Haugas, M., Matilainen, T., Pussinen, C., Karis, A., Salminen, M., 2006.
Gata3 is required for early morphogenesis and Fgf10 expression during otic
development. Mech. Dev. 123, 415–429.
Lillevali, K., Matilainen, T., Karis, A., Salminen, M., 2004. Partially overlapping expression
of Gata2 and Gata3 during inner ear development. Dev. Dyn. 231, 775–781.
Liu, D., Chu, H., Maves, L., Yan, Y.L., Morcos, P.A., Postlethwait, J.H., Westerﬁeld, M.,
2003. Fgf3 and Fgf8 dependent and independent transcription factors are
required for otic placode speciﬁcation. Development 130, 2213–2224.Mansour, S.L., Goddard, J.M., Capecchi, M.R., 1993. Mice homozygous for a targeted
disruption of the proto-oncogene int-2 have developmental defects in the tail
and inner ear. Development 117, 13–28.
Nardelli, J., Thiesson, D., Fujiwara, Y., Tsai, F.Y., Orkin, S.H., 1999. Expression and
genetic interaction of transcription factors GATA-2 and GATA-3 during devel-
opment of the mouse central nervous system. Dev. Biol. 210, 305–321.
Nonchev, S., Maconochie, M., 1999. Spatial analysis of gene expression. In: Jackson,
I.J., Abbott, C.M (Eds.), Mouse Genetics and Transgenics: A Practical Approach.
Oxford University Press, pp. 61–86.
Ohuchi, H., Yasue, A., Ono, K., Sasaoka, S., Tomonari, S., Takagi, A., Itakura, M.,
Moriyama, K., Noji, S., Nohno, T., 2005. Identiﬁcation of cis-element regulating
expression of the mouse Fgf10 gene during inner ear development. Dev. Dyn.
233, 177–187.
Ohyama, T., Groves, A.K., Martin, K., 2007. The ﬁrst steps towards hearing:
mechanisms of otic placode induction. Int. J. Dev. Biol. 51, 463–472.
Pata, I., Studer, M., van Doorninck, J.H., Briscoe, J., Kuuse, S., Engel, J.D., Grosveld, F.,
Karis, A., 1999. The transcription factor GATA3 is a downstream effector of
Hoxb1 speciﬁcation in rhombomere 4. Development 126, 5523–5531.
Pauley, S., Wright, T., Pirvola, U., Ornitz, D., Biesel, K., Fritzsch, B., 2003. Expression
and function of FGF10 in mammalian inner ear development. Dev. Dyn. 227,
203–215.
Quandt, K., Frech, K., Karas, H., Wingender, E., Werner, T., 1995. MatInd and
MatInspector: New fast and versatile tools for detection of consensus matches
in nucleotide sequence data. Nucleic Acids Res. 23, 4878–4884.
Romand, R., Dolle, P., Hashino, E., 2006a. Retinoid signaling in inner ear develop-
ment. J. Neurobiol. 66, 687–704.
Romand, R., Kondo, T., Fraulob, V., Petkovich, M., Dolle, P., Hashino, E., 2006b.
Dynamic expression of retinoic acid-synthesizing and -metabolizing enzymes
in the developing mouse inner ear. J. Comp. Neurol. 496, 643–654.
Sasak, H., Yamaoka, T., Ohuchi, H., Yasue, A., Nohno, T., Kawano, H., Kato, S.,
Itakura, M., Nagayama, M., Noji, S., 2002. Identiﬁcation of cis-elements
regulating expression of Fgf10 during limb development. Int. J. Dev. Biol. 46,
963–967.
Schimmang, T., 2007. Expression and functions of FGF ligands during early otic
development. Int. J. Dev. Biol. 51, 473–481.
Sweet, E.M., Vemaraju, S., Riley, B.B., 2011. Sox2 and Fgf interact with Atoh1 to
promote sensory competence throughout the zebraﬁsh inner ear. Dev. Biol.
358, 113–121.
Torres, M., Giraldez, F., 1998. The development of the vertebrate inner ear. Mech.
Dev. 71, 5–21.
Tsai, F.Y., Keller, G., Kuo, F.C., Weiss, M., Chen, J., Rosenblatt, M., Alt, F.W., Orkin,
S.H., 1994. An early haematopoietic defect in mice lacking the transcription
factor GATA-2. Nature 371, 221–226.
Urness, L.D., Bleyl, S.B., Wright, T.J., Moon, A.M., Mansour, S.L., 2011. Redundant
and dosage sensitive requirements for Fgf3 and Fgf10 in cardiovascular
development. Dev. Biol. 356, 383–397.
Wood, H., Pall, G., Morriss-Kay, G., 1994. Exposure to retinoic acid before or after
the onset of somitogenesis reveals separate effects on rhombomeric segmen-
tation and 30 HoxB gene expression domains. Development 120, 2279–2285.
Wright, T.J., Mansour, S.L., 2003. Fgf3 and Fgf10 are required for mouse otic
placode induction. Development 130, 3379–3390.
Zelarayan, L.C., Vendrell, V., Alvarez, Y., Dominguez-Frutos, E., Theil, T., Alonso,
M.T., Maconochie, M., Schimmang, T., 2007. Differential requirements for
FGF3, FGF8 and FGF10 during inner ear development. Dev. Biol. 308, 379–391.
